Sugi Predict

Sugi Predict / Compounds / SCHEMBL4084851

SCHEMBL4084851

SCHEMBL4084851

CCN(CC)CCn1c(=O)c(-c2ccccc2Cl)cc2cnc(NC3C4CN(C(C)=O)CC43)nc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 8/20 0.52
▸ FGFR2 P21802 6/20 0.52
▸ FGFR4 P22455 3/20 0.52
▸ FGFR3 P22607 3/20 0.52
▸ KDR P35968 2/20 0.52
▸ PAK1 Q13153 2/20 0.51
▸ RIPK2 O43353 4/20 0.50
▸ ACVR1 Q04771 4/20 0.50
▸ NOD2 Q9HC29 4/20 0.50
▸ SIK1 P57059 1/20 0.50
▸ SIK2 Q9H0K1 1/20 0.50
▸ SIK3 Q9Y2K2 1/20 0.50
▸ TNK2 Q07912 2/20 0.48
▸ LCK P06239 1/20 0.47
▸ MAPK14 Q16539 1/20 0.47
▸ EGFR P00533 1/20 0.44
▸ SRC P12931 1/20 0.44
▸ HDAC3 O15379 1/20 0.44
▸ PAK3 O75914 1/20 0.44
▸ PAK2 Q13177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4092205 0.88 FGFR2 (0.52) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL4084178 0.86 MAPK14 (0.63) FGFR1FGFR2FGFR4FGFR3PAK1
SCHEMBL4097349 0.82 LCK (0.51) FGFR1PAK1RIPK2ACVR1NOD2
SCHEMBL13849301 0.79 MAPK14 (0.47) FGFR1PAK1RIPK2ACVR1NOD2
SCHEMBL4101345 0.79 MAPK14 (0.63) FGFR1FGFR2FGFR4FGFR3PAK1
SCHEMBL13849317 0.79 LCK (0.59) FGFR1FGFR2FGFR4FGFR3PAK1
SCHEMBL4089651 0.78 MAPK14 (0.57) FGFR1FGFR2FGFR4FGFR3PAK1
SCHEMBL4102846 0.78 PAK1 (0.47) FGFR1FGFR2PAK1SIK1SIK2
SCHEMBL4094179 0.77 SIK2 (0.42) FGFR1PAK1SIK1SIK2SIK3
SCHEMBL4089649 0.76 MAPK14 (0.59) FGFR1FGFR2FGFR4FGFR3PAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US claimed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 — — US disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 — — EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 FGFR1 1184/4885FGFR2 2524/4885FGFR4 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.